Kaleido Biosciences, Inc. (KLDO)
- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0000 - 0.0300 - Volume
124 - Avg. Volume
2,712 - Market Cap (intraday)
4,262 - Beta (5Y Monthly) 36.97
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
kaleido.comRelated News
Performance Overview: KLDO
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KLDO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KLDO
Valuation Measures
Market Cap
4.26k
Enterprise Value
-16.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
-15.20
Enterprise Value/EBITDA
0.20
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-99.93%
Return on Equity (ttm)
-580.57%
Revenue (ttm)
1.1M
Net Income Avi to Common (ttm)
-90.29M
Diluted EPS (ttm)
-2.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
38.47M
Total Debt/Equity (mrq)
204.52%
Levered Free Cash Flow (ttm)
-46.02M